LGC now offers proficiency testing samples for the detection of SARS-CoV-2 (COVID-19) by nucleic acid amplification testing. Novachem as distributor for LGC in Australia and New Zealand is pleased to be able to offer participation in this scheme. Samples are non-infectious and are compatible with molecular assays that target CDC and WHO consensus gene sequence regions ORF1a, RdRp, E (Envelope), N (Nucleocapsid) and/or S (Spike).
As increasing numbers of diagnostic methods are made available in the global fight against COVID-19 it is essential that laboratories ensure that their application of methods and subsequent results are reliable and accurate using external quality assurance tools including proficiency testing.
SARS-CoV-2 (molecular)
Qualitative reporting for COVID-19 detection.
“Governments, health bodies, hospitals, virology labs and indeed most of the world’s population find themselves locked in a war with the novel virus COVID-19.
“LGC is now directly involved in COVID-19 related work, from supporting diagnostic kit manufacturers, diagnostic testing and clinical research to providing quality assurance tools to ensure reliability of measurements being made. It is our hope that by using this new proficiency testing program for SARS-CoV-2, external quality assurance measures will be in place for all clinical laboratories worldwide.
“Together we can ensure the accurate and reliable testing of patients as the world unites to prevent loss of life.”
Brian Brookman, Director, Proficiency Testing, LGC
New SARS-CoV-2 (molecular) Sample
Clinical Microbiological Proficiency Test